Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$48.14M+167.62%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Wenbin Jiang
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 682
- Beta
- 1.19
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 4.11
Financials
Revenue
$48.14M+167.6%Net Income
$-12.16MEBITDA
$-8.38MFree Cash Flow
$-849.0K-177.4%EPS (diluted)
$-0.09Shares Outstanding (diluted)
129.46M+5.2%Operating Expenses
$39.74MCash & Debt
$262.00MReturn of Capital
$0.00Revenue by Segment (annual)
$201.49MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $201.49M | $-66.54M | $-0.52 |
| 2024 | $200.45M | $-6.02M | $-0.05 |
| 2023 | $193.01M | $-12.15M | $-0.09 |
| 2022 | $164.04M | $2.58M | $0.02 |
| 2021 | $127.95M | $3.00M | $0.03 |
| 2020 | $92.84M | $19.41M | $0.02 |
| 2019 | $57.88M | $-16.83M | $-0.13 |
Valuation
CTKBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·12d ago·Neutral
Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool Cytek has expanded its Cytek® Cloud digital ecosystem with a new Cloud Analysis tool to create the industry's first end-to-end flow cytometry platform.
View source ↗ - Newszacks.com·18d ago·Negative
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock? Investors need to pay close attention to CTKB stock based on the movements in the options market lately.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry FREMONT, Calif., and HAMBURG, Germany, Sept.
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
… seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced solutions at two leading clinical cytometry events this fall: the European Society for Clinical Cell Analysis (ESCCA) 2026 Conference and ICCS 2026, the 41st Annual International Clinical Cytometry Meeting & Course.
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Cytek Biosciences to Participate in Upcoming Investor Conferences FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
…y to Challenge Remaining Finding FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in Cytek's favor on three of the four asserted patent claims, finding noninfringement and …
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.07 per share
Typical surprise -50.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.05 vs $-0.09beat
- Thu, May 7$-0.12 vs $-0.08miss
- Thu, Feb 26$-0.34 vs $-0.02miss
- Wed, Nov 5$-0.01 vs $-0.03beat
- Wed, Aug 6$-0.04 vs $-0.02miss
- Thu, May 8$-0.09 vs $-0.04miss
Estimates and results for CTKB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CTKB officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CTKB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.